Back to Authors

Patnaik, Mrinal M.

https://orcid.org/0000-0001-6998-662X

A5072463255 | I1330342723

Mayo Clinic

Mayo Clinic

Citations 648

Venetoclax plus hypomethylating agents in DDX41‐mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

British Journal of Haematology | September 15, 2023 | Volume: 204 | Issue: 1 | Pages: 171-176

10.1111/bjh.19105 | PMID 37710381

SummaryVenetoclax (VEN) is an FDA‐approved selective inhibitor of B‐cell leukaemia/lymphoma‐2 (BCL‐2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high‐risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating DDX41‐mutated (mDDX41) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of mDDX41 MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach.
Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies

American Journal of Hematology | September 14, 2023 | Volume: 98 | Issue: 11 | Pages: 1673-1676

10.1002/ajh.27091 | PMID 37705260

Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome

American Journal of Hematology | September 9, 2023 | Volume: 99 | Issue: 1 | Pages: No page available

10.1002/ajh.27089 | PMID 37688525

Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants

American Journal of Hematology | September 4, 2023 | Volume: 98 | Issue: 12 | Pages: No page available

10.1002/ajh.27086 | PMID 37665761

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE

HemaSphere | August 25, 2023 | Volume: 7 | Issue: S3 | Pages: e81209ff

10.1097/01.hs9.0000969892.81209.ff

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e8757030

10.1097/01.hs9.0000969792.87570.30

P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e5593144

10.1097/01.hs9.0000969740.55931.44

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e84724f8

10.1097/01.hs9.0000969224.84724.f8

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS

HemaSphere | August 10, 2023 | Volume: 7 | Issue: S3 | Pages: e6718317

10.1097/01.hs9.0000967964.67183.17

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE

HemaSphere | August 10, 2023 | Volume: 7 | Issue: S3 | Pages: e65989e7

10.1097/01.hs9.0000969840.65989.e7